Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -64,342 | -281,310 | -218,212 | -143,836 | -71,639 |
| Depreciation Amortization | 5,797 | 21,192 | 15,353 | 9,801 | 4,496 |
| Accounts receivable | -1,123 | -1,519 | 171 | 1,188 | -3,357 |
| Accounts payable and accrued liabilities | -930 | -1,824 | -4,578 | -4,090 | -4,996 |
| Other Working Capital | -17,246 | -4,774 | -6,721 | -11,762 | -18,278 |
| Other Operating Activity | 16,574 | 46,697 | 37,060 | 24,939 | 19,019 |
| Operating Cash Flow | $-61,270 | $-221,538 | $-176,927 | $-123,760 | $-74,755 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,456 | -10,375 | -6,018 | -5,016 | -4,036 |
| Purchase Of Investment | -22,016 | -183,590 | -178,588 | -168,597 | -87,384 |
| Sale Of Investment | 72,000 | 172,000 | 135,000 | 103,000 | 53,000 |
| Other Investing Activity | -3,960 | -7,700 | -7,700 | -3,500 | 0 |
| Investing Cash Flow | $44,568 | $-29,665 | $-57,306 | $-74,113 | $-38,420 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 98,150 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 9,076 | 38,394 | 36,735 | 36,422 | 32,842 |
| Other Financing Activity | -1,913 | -8,525 | -7,271 | -4,466 | -3,798 |
| Financing Cash Flow | $105,313 | $29,869 | $29,464 | $31,956 | $29,044 |
| Beginning Cash Position | 115,669 | 337,003 | 337,003 | 337,003 | 337,003 |
| End Cash Position | 204,280 | 115,669 | 132,234 | 171,086 | 252,872 |
| Net Cash Flow | $88,611 | $-221,334 | $-204,769 | $-165,917 | $-84,131 |
| Free Cash Flow | |||||
| Operating Cash Flow | -61,270 | -221,538 | -176,927 | -123,760 | -74,755 |
| Capital Expenditure | -1,456 | -10,375 | -6,018 | -5,016 | -4,036 |
| Free Cash Flow | -62,726 | -231,913 | -182,945 | -128,776 | -78,791 |